Company profile
Digostics - Lab quality diabetes testing, at home.
Digostics offers the world's first and only alternative to clinic oral glucose tolerance testing (OGTT) by enabling this crucial test to be performed at home.
Financial period: 1 Jan 2024 to 31 Dec 2024
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
SH01 | Transaction MzUxMjUwNzA3NGFkaXF6a2N4
Published 25 Mar 2026 11:10
Last confirmation statement made up date
Last accounts made up date
SH01 | Transaction MzQ0NDA4MTI1NWFkaXF6a2N4
Published 19 Nov 2024 09:09
MR04 | Transaction MzQ0MTg2NDc3NmFkaXF6a2N4
Published 04 Nov 2024 09:58
AAMD | Transaction MzQ0MTEzMzA5M2FkaXF6a2N4
Published 28 Oct 2024 03:22
AA | Transaction MzQzNzY2OTkwMmFkaXF6a2N4
Published 30 Sep 2024 06:44
RP04CS01 | Transaction MzQzNjgzMzA3OWFkaXF6a2N4
Published 25 Sep 2024 07:44
CS01 | Transaction MzQxNTY0MTQzOGFkaXF6a2N4 | Paper/PDF filed
Published 26 Sep 2024 06:16
Company registered at Companies House
1 Nov 2022 to 30 Apr 2023
The vision of this project is to evaluate a safe and efficient screening system for type 1 diabetes (T1D). Digostics is working with Oxford and Yale universities to incorporate its novel GTT@home product into home-based T1D screening; GTT@home is seen as a major step forward, replacing in-clinic oral glucose tolerance test (OGTT), a major barrier to testi...
